⌘+K

Pulse Explore Communities Researchers Journals

Browser extensionInstagram

Home Communities Explore

January 20, 2016Antimicrobial Agents and ChemotherapyOpen Access

The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In Vitro Activity against Cryptococcus neoformans and Cryptococcus gattii

Shawn R. Lockhart Annette W. Fothergill Naureen Iqbal Carol B. Bolden Nina T. Grossman Edward P. Garvey Stephen Brand William J. Hoekstra Robert J. Schotzinger Elizabeth A. Ottinger Thomas F. Patterson Nathan P. Wiederhold

View Full Paper

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

Thein vitroactivities of the novel fungal Cyp51 inhibitor VT-1129 were evaluated against a large panel ofCryptococcus neoformansandCryptococcus gattiiisolates. VT-1129 demonstrated potent activities against bothCryptococcusspecies as demonstrated by low MIC50and MIC90values. ForC. gattii, thein vitropotency was maintained against all genotypes. In addition, significantly lower geometric mean MICs were observed for VT-1129 than for fluconazole againstC. neoformans, including isolates with reduced fluconazole susceptibility.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lockhart et al. (2016) studied this question.

synapsesocial.com/papers/6a74900f8d2049c8dd032c14 https://doi.org/10.1128/aac.02770-15

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Rosmarinic acid exerts anti-CVB3 effects by inducing HO-1 via the SIRT1/AMPKα/Nrf2 pathwayAntimicrobial Agents and Chemotherapy · 2026
2Dual-effective kinase inhibitors as potential treatment of giardiasis and cryptosporidiosisAntimicrobial Agents and Chemotherapy · 2026
3In vitro activity of manogepix against Candida spp. displaying elevated echinocandin MIC resultsAntimicrobial Agents and Chemotherapy · 2026
4Population pharmacokinetic analysis of lamivudine (3TC) in HIV-exposed neonates and pediatric participants living with HIV-1 from the IMPAACT 2019 and PETITE studiesAntimicrobial Agents and Chemotherapy · 2026
5SCY-247, a second-generation triterpenoid antifungal, shows low risk for clinically meaningful interactions with CYP3A4 substrates: results from a phase 1 midazolam drug-drug interaction studyAntimicrobial Agents and Chemotherapy · 2026
6Reducing bacterial resistance evolution through antimicrobial peptide modificationsAntimicrobial Agents and Chemotherapy · 2026
7Mining and engineering novel staphylococcal lysostaphins as species-specific antibacterial agentsAntimicrobial Agents and Chemotherapy · 2026
8Population pharmacokinetic modeling of abacavir in HIV-exposed neonates and children with HIV-1 using data from the IMPAACT 2019 and PETITE studiesAntimicrobial Agents and Chemotherapy · 2026
9Functional export of NDM-7 to outer membrane vesicles in Klebsiella pneumoniae compromises imipenem and cefiderocol activityAntimicrobial Agents and Chemotherapy · 2026
10A substrate-dependent mechanism of inhibition of the polyspecific multidrug efflux pump MexF from Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy · 2026

More from Antimicrobial Agents and Chemotherapy

More from National Institutes of Health

More from Centers for Disease Control and Prevention

More from The University of Texas Health Science Center at San Antonio

More from South Texas Veterans Health Care System

More from Viamet Pharmaceuticals (United States)